Reference
Laskey RA, et al. Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity. OncoTargets and Therapy 7: 469-476, 21 Mar 2014. Available from: URL: http://doi.org/10.2147/OTT.S57425 - USA
Rights and permissions
About this article
Cite this article
Bevacizumab. Reactions Weekly 1515, 45 (2014). https://doi.org/10.1007/s40278-014-2740-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-014-2740-2